Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.

Autor:	Nief CA; Stanford University School of Medicine, Stanford, California.; Department of Pathology, Stanford University, Stanford, California., Hammer PM; Department of Pathology, Stanford University, Stanford, California., Wang A; Department of Pathology, Stanford University, Stanford, California., Charu V; Department of Pathology, Stanford University, Stanford, California., Tanweer A; Department of Pathology, Stanford University, Stanford, California., Litkouhi B; Department of Biomedical Data Science, Stanford University, Stanford, California., Kidd E; Department of Radiation Oncology, Stanford University, Stanford, California., Gentles AJ; Department of Pathology, Stanford University, Stanford, California.; Department of Gynecologic Oncology, Stanford University, Stanford, California., Howitt BE; Department of Pathology, Stanford University, Stanford, California.
Jazyk:	angličtina
Zdroj:	Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jul 01; Vol. 30 (13), pp. 2801-2811.
DOI:	10.1158/1078-0432.CCR-23-3158
Abstrakt:	Purpose: Risk prediction with genomic and transcriptomic data has the potential to improve patient outcomes by enabling clinicians to identify patients requiring adjuvant treatment approaches, while sparing low-risk patients from unnecessary interventions. Endometrioid endometrial carcinoma (EEC) is the most common cancer in women in developed countries, and rates of endometrial cancer are increasing. Experimental Design: We collected a 105-patient case-control cohort of stage I EEC comprising 45 patients who experienced recurrence less than 6 years after excision, and 60 Fédération Internationale de Gynécologie et d'Obstétrique grade-matched controls without recurrence. We first utilized two RNA-based, previously validated machine learning approaches, namely, EcoTyper and Complexity Index in Sarcoma (CINSARC). We developed Endometrioid Endometrial RNA Index (EERI), which uses RNA expression data from 46 genes to generate a personalized risk score for each patient. EERI was trained on our 105-patient cohort and tested on a publicly available cohort of 263 patients with stage I EEC. Results: EERI was able to predict recurrences with 94% accuracy in the training set and 81% accuracy in the test set. In the test set, patients assigned as EERI high-risk were significantly more likely to experience recurrence (30%) than the EERI low-risk group (1%) with a hazard ratio of 9.9 (95% CI, 4.1-23.8; P < 0.001). Conclusions: Tumors with high-risk genetic features may require additional treatment or closer monitoring and are not readily identified using traditional clinicopathologic and molecular features. EERI performs with high sensitivity and modest specificity, which may benefit from further optimization and validation in larger independent cohorts. (©2024 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu